Acid-suppressive effects of rabeprazole: Comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers

Digestive and Liver Disease

Volumn 38, Issue 11, 2006, Pages 802-808

  Shimatani, T ^a   Moriwaki, M ^b   Xu, J ^b   Tazuma, S ^a   Inoue, M ^c  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Hiroshima Pref Agricultural Center   (Japan)

Author keywords

Cytochrome P 450 2C19 (CYP2C19); Helicobacter pylori (H. pylori); Intragastric pH; Nocturnal acid breakthrough (NAB); Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; PLACEBO; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INHIBITION KINETICS; JAPAN; MONITORING; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; STOMACH ACID; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; JAPAN; MIXED FUNCTION OXYGENASES; PEPSINOGEN A; PEPSINOGEN C; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTON-TRANSLOCATING ATPASES; STOMACH;

EID: 33748921737     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.06.002     Document Type: Article

References (39)

1. Lam S.K., and Talley N.J. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13 (1998) 1-12
2. Malfertheiner P., Megraud F., O'Morain C., Hungin A.P., Jones R., Axon A., et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
3. Fujisaki H., Shibata H., Oketani K., Murakami M., Fujimoto M., Wakabayashi T., et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 42 (1991) 321-328
4. Morii M., Hamatani K., and Takeguchi N. The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+, K(+)-ATPase. Biochem Pharmacol 49 (1995) 1729-1734
5. Williams M.P., Blanshard C., Millson C., Sercombe J., and Pounder R.E. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 14 (2000) 691-699
6. Ohning G.V., Barbuti R.C., Kovacs T.O., Sytnik B., Humphries T.J., and Walsh J.H. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 14 (2000) 701-708
7. Gambaro C., Bilardi C., Dulbecco P., Iiritano E., Zentilin P., Mansia C., et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig Liver Dis 35 (2003) 763-767
8. Pace F., Annese V., Prada A., Zambelli A., Casalini S., Nardini P., et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis 37 (2005) 741-750
9. Shimatani T., Inoue M., Kuroiwa T., Xu J., Tazuma S., Horikawa Y., et al. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-h intragastric pH-metry. Dig Dis Sci 50 (2005) 1202-1206
10. Shimatani T., Inoue M., Kuroiwa T., Xu J., Mieno H., Nakamura M., et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 79 (2006) 144-152
11. Miwa H., Yamada T., Sato K., Ohta K., Ohkura R., Murai T., et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 45 (2000) 77-82
12. Hokari K., Sugiyama T., Kato M., Saito M., Miyagishima T., Kudo M., et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 15 (2001) 1479-1484
13. Murakami K., Sato R., Okimoto T., Nasu M., Fujioka T., Kodama M., et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16 (2002) 1933-1938
14. Mario F.D., Dal Bo N., Aragona G., Moussa A.M., Iori V., Cavestro G.M., et al. Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. J Gastroenterol Hepatol 18 (2003) 783-786
15. Wong W.M., Huang J., Xia H.H., Fung F.M., Tong T.S., Cheung K.L., et al. Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients. J Gastroenterol Hepatol 20 (2005) 935-940
16. Adachi K., Fujishiro H., Katsube T., Yuki M., Ono M., Kawamura A., et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16 (2001) 1191-1196
17. Peghini P.L., Katz P.O., Bracy N.A., and Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93 (1998) 763-767
18. Adachi K., Komazawa Y., Fujishiro H., Mihara T., Ono M., Yuki M., et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol 38 (2003) 830-835
19. Shimatani T., Inoue M., Kuroiwa T., and Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 19 (2004) 113-122
20. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
21. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269 (1994) 15419-15422
22. Kubota T., Chiba K., and Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60 (1996) 661-666
23. Miki K., and Ichinose M. Chronic atrophic gastritis and serum pepsinogen levels. Jpn J Cancer Clin 38 (1992) 221-229 (in Japanese with English abstract)
24. Miki K., Ichinose M., Kakei N., Yahagi N., Matsushima M., Tsukada S., et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. In: Takahashi K. (Ed). Aspartic proteinases: structure, function, biology and biomedical implications (1995), Plenum Press, New York 139-143
25. Kekki M., Samloff I.M., Varis K., and Ihamaki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl 186 (1991) 109-116
26. Yasuda S., Ohnishi A., Ogawa T., Tomono Y., Hasegawa J., Nakai H., et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 32 (1994) 466-473
27. Labenz J., Stolte M., Blum A.L., Jorias I., Leverkus F., Sollbohmer M., et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 37 (1995) 39-43
28. Miwa H., Nagahara A., Sato K., Ohkura R., Murai T., Shimizu H., et al. Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 14 (1999) 317-321
29. Sieg A., Sellinger M., Schlauch D., Horner M., and Fuchs W. Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. Aliment Pharmacol Ther 13 (1999) 865-868
30. Chiba N., and Marshall C.P. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 14 (2000) 27-31
31. Sjostedt S., Sagar M., Lindberg G., Wikstrom B., Nord C.E., and Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol 33 (1998) 39-43
32. Hatlebakk J.G., Katz P.O., and Castell D.O. Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am 28 (1999) 847-860
33. Bell N.J., Burget D., Howden C.W., Wilkinson J., and Hunt R.H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 (1992) 59-67
34. El-Omar E.M., Penman I.D., Ardill J.E., Chittajallu R.S., Howie C., and McColl K.E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 (1995) 681-691
35. El-Omar E.M., Oien K., El-Nujumi A., Gillen D., Wirz A., Dahill S., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997) 15-24
36. Verdu E.F., Armstrong D., Fraser R., Viani F., Idstrom J.P., Cederberg C., et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36 (1995) 539-543
37. Verdu E.F., Armstrong D., Idstrom J.P., Labenz J., Stolte M., Dorta G., et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37 (1995) 743-748
38. Gillen D., Wirz A.A., Neithercut W.D., Ardill J.E., and McColl K.E. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44 (1999) 468-475
39. Williams M.P., Usselmann B., Chilton A., Sercombe J., Nwokolo C.U., and Pounder R.E. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther 17 (2003) 775-783